Bank of Montreal Can Has $317,000 Stock Position in Inari Medical, Inc. (NASDAQ:NARI)

Bank of Montreal Can raised its stake in Inari Medical, Inc. (NASDAQ:NARI) by 7.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,212 shares of the company’s stock after buying an additional 450 shares during the quarter. Bank of Montreal Can’s holdings in Inari Medical were worth $317,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Smartleaf Asset Management LLC raised its stake in shares of Inari Medical by 128.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 634 shares of the company’s stock valued at $33,000 after purchasing an additional 356 shares during the period. R Squared Ltd acquired a new stake in shares of Inari Medical in the fourth quarter valued at approximately $45,000. Quadrant Capital Group LLC boosted its position in Inari Medical by 12.3% during the fourth quarter. Quadrant Capital Group LLC now owns 1,301 shares of the company’s stock worth $66,000 after purchasing an additional 143 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Inari Medical by 66.8% during the 4th quarter. GAMMA Investing LLC now owns 1,963 shares of the company’s stock worth $100,000 after buying an additional 786 shares during the period. Finally, KBC Group NV raised its holdings in Inari Medical by 31.5% in the 4th quarter. KBC Group NV now owns 2,333 shares of the company’s stock valued at $119,000 after acquiring an additional 559 shares during the period. 90.98% of the stock is owned by institutional investors.

Inari Medical Price Performance

Shares of NASDAQ:NARI opened at $79.97 on Thursday. The company has a market cap of $4.68 billion, a PE ratio of -59.24 and a beta of 1.02. Inari Medical, Inc. has a 1 year low of $37.04 and a 1 year high of $79.99. The stock’s 50-day moving average is $79.97 and its 200 day moving average is $66.26.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on NARI shares. Baird R W cut Inari Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 7th. Piper Sandler lifted their target price on Inari Medical from $52.00 to $80.00 and gave the stock a “neutral” rating in a report on Tuesday, January 7th. Robert W. Baird reiterated a “neutral” rating and set a $80.00 price target (down from $81.00) on shares of Inari Medical in a report on Tuesday, January 7th. Wells Fargo & Company reiterated an “equal weight” rating and issued a $80.00 target price (up from $65.00) on shares of Inari Medical in a report on Tuesday, January 7th. Finally, Canaccord Genuity Group reiterated a “hold” rating and set a $80.00 target price (up previously from $74.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Twelve research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $68.00.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.